 |
인쇄하기
취소
|
Hanmi-Sanofi, First ‘ARB-Statin’ FDC new drug approval
‘Robelito’ appointed reexamination in 6 years, local co-marketing
(The Yakup Shinmoon)
The fixed dose combination (FDC) of hypertension drug Irbesratan and hyperlipidemia drug Atorvastatin get approved to sell in Korea first ever.
Hanmi and Sanofi revealed on the November 7 that the marketing authorization of Robelito which had been developed jointly with Hanmi and Sanofi obtained from ...
(The Yakup Shinmoon)
The fixed dose combination (FDC) of hypertension drug Irbesratan and hyperlipidemia drug Atorvastatin get approved to sell in Korea first ever.
Hanmi and Sanofi revealed on the November 7 that the marketing authorization of Robelito which had been developed jointly with Hanmi and Sanofi obtained from ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.